作者: William R. Waud
DOI: 10.1007/978-1-60761-968-0_2
关键词: Clinical trial 、 P388 leukemia 、 Anticancer drug 、 Drug resistance 、 Cancer research 、 Human leukemia 、 Medicine 、 Combination chemotherapy 、 Human cancer 、 Leukemia
摘要: L1210 and P388 leukemia models have been extensively used over the last 50 years. The are rapid, reproducible, relatively inexpensive (in comparison to human tumor xenograft transgenic models). However, as with any experimental animal model, there limitations. Neither is a satisfactory model for either cancer in general or particular. Despite limitations of murine models, these useful making progress anticancer drug development, development number therapeutic principles, understanding biologic behavior host. These still today conducting detailed evaluations new candidate drugs (e.g., schedule dependency, route administration formulation comparison, analog combination chemotherapy). greatest utility leukemias derived from drug-resistant sublines crossresistance collateral sensitivity. Crossresistance data, coupled knowledge resistance mechanisms operative leukemias, may yield insights into action agents. Similarly, various agents, leukemias. Furthermore, data identify potentially guides patient selection clinical trials antitumor drugs.